Home Stock

Stock Research: JW Pharmaceutical

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

JW Pharmaceutical

KSC:001060 KR7001060003
29
  • Value
    24
  • Growth
    67
  • Safety
    Safety
    40
  • Combined
    32
  • Sentiment
    63
  • 360° View
    360° View
    29
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

JW Pharmaceutical Corp develops and manufactures pharmaceuticals. The company operates in the pharmaceutical industry, producing drugs for various treatments. Based in Korea, the company also researches anticancer drugs. In the last fiscal year, the company had a market cap of $416 million, profits of $219 million, and revenue of $487 million. The number of employees is unavailable.

more

ANALYSIS: With an Obermatt 360° View of 29 (better than 29% compared with alternatives), overall professional sentiment and financial characteristics for the stock JW Pharmaceutical are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for JW Pharmaceutical. The consolidated Growth Rank has a good rank of 67, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 67% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 63, which means that professional investors are more optimistic about the stock than for 63% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 24, which means that the share price of JW Pharmaceutical is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 76% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 40, which means that the company has a financing structure that is riskier than those of 60% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Analyst Opinions
Country South Korea
Industry Pharmaceuticals
Size Small
Website jw-pharma.co.kr
Index
KOSPI
JW Pharmaceutical stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
24 68 42 53
Growth
67 55 59 23
Safety
Safety
40 52 12 16
Sentiment
63 74 61 84
360° View
360° View
29 78 34 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
93 100 91 71
Opinions Change
50 33 29 50
Pro Holdings
n/a 70 64 65
Market Pulse
83 1 n/a n/a
Sentiment
63 74 61 84
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
24 68 42 53
Growth
67 55 59 23
Safety Safety
40 52 12 16
Combined
32 72 23 8
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
46 87 68 92
Price vs. Earnings (P/E)
57 90 58 81
Price vs. Book (P/B)
23 29 25 30
Dividend Yield
1 44 37 40
Value
24 68 42 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
74 64 63 53
Profit Growth
75 42 45 23
Capital Growth
23 100 3 72
Stock Returns
75 10 99 17
Growth
67 55 59 23
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
70 28 3 6
Refinancing
20 34 25 53
Liquidity
59 80 26 8
Safety Safety
40 52 12 16

Similar Stocks

Discover high‑ranked alternatives to JW Pharmaceutical and broaden your portfolio horizons.

Daiwa House

TYO:1925
Country: Japan
Industry: Electric Utilities
Size: XX-Large
Full Stock Analysis

Kinden

TYO:1944
Country: Japan
Industry: Construction & Engineering
Size: X-Large
Full Stock Analysis

Shionogi

TYO:4507
Country: Japan
Industry: Pharmaceuticals
Size: X-Large
Full Stock Analysis

Youngone

KSC:111770
Country: South Korea
Industry: Apparel, Accessories, Luxury
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This is a classic, high-risk growth play: high growth and positive sentiment outweigh low Value Rank (expensive) and risky financing. This is for aggressive growth investors who are comfortable with the high price and risk, believing the growth story justifies the expense.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews